AR039713A1 - Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina - Google Patents

Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina

Info

Publication number
AR039713A1
AR039713A1 ARP030102197A ARP030102197A AR039713A1 AR 039713 A1 AR039713 A1 AR 039713A1 AR P030102197 A ARP030102197 A AR P030102197A AR P030102197 A ARP030102197 A AR P030102197A AR 039713 A1 AR039713 A1 AR 039713A1
Authority
AR
Argentina
Prior art keywords
insulin resistance
orto
benzoic acid
acid derivatives
derivatives substituted
Prior art date
Application number
ARP030102197A
Other languages
English (en)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201935A external-priority patent/SE0201935D0/xx
Priority claimed from SE0203826A external-priority patent/SE0203826D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR039713A1 publication Critical patent/AR039713A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee un compuesto de la fórmula (1) donde n es 0, 1 o 2 y R1 representa halo, un grupo C1-4alquilo que está sustituido optativamente con uno o más átomos de flúor, un grupo C1-4alcoxi que está sustituido optativamente con uno o más átomos de flúor y donde, cuando n vale 2 los sustituyentes R1 pueden ser iguales o diferentes; R2 representa un grupo C2-8alquilo interrumpido optativamente por oxígeno; Y está ausente o representa metileno; y X es O o S; y las sales y profármacos aceptables para uso farmacéutico de los mismos; procesos para preparar dichos compuestos, su utilidad en el tratamiento de las afecciones clínicas asociadas con resistencia a insulina, con métodos para su uso terapéutico y con composiciones farmacéuticas que contienen dichos compuestos.
ARP030102197A 2002-06-20 2003-06-20 Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina AR039713A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201935A SE0201935D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
SE0203826A SE0203826D0 (sv) 2002-12-20 2002-12-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR039713A1 true AR039713A1 (es) 2005-03-09

Family

ID=30002442

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102197A AR039713A1 (es) 2002-06-20 2003-06-20 Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina

Country Status (23)

Country Link
US (1) US7355069B2 (es)
EP (1) EP1517883B8 (es)
JP (2) JP3782818B2 (es)
KR (1) KR20050014013A (es)
CN (1) CN1319938C (es)
AR (1) AR039713A1 (es)
AT (1) ATE386013T1 (es)
AU (1) AU2003240099B2 (es)
BR (1) BR0311932A (es)
CA (1) CA2489834C (es)
DE (1) DE60319084T2 (es)
DK (1) DK1517883T3 (es)
ES (1) ES2299702T3 (es)
HK (1) HK1073838A1 (es)
IL (1) IL165671A0 (es)
IS (1) IS7627A (es)
MX (1) MXPA04012686A (es)
NO (1) NO20045353L (es)
PL (1) PL375074A1 (es)
PT (1) PT1517883E (es)
RU (1) RU2004137094A (es)
TW (1) TWI282784B (es)
WO (1) WO2004000790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2875805B1 (fr) * 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
GB0522431D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Chemical process
GB0522433D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Therapeutic agents

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
CA2306825A1 (en) 1997-10-17 1999-04-29 Avantis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
PL341044A1 (en) 1997-12-19 2001-03-26 Schering Ag Derivatives of orthoantranilic amide as anticoagulants
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
JP4598278B2 (ja) 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
SK15522001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0116955D0 (en) 2001-07-11 2001-09-05 Syngenta Ltd Weed control process
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
NZ531796A (en) 2001-09-08 2005-10-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
WO2004000790A1 (en) 2003-12-31
CA2489834A1 (en) 2003-12-31
PT1517883E (pt) 2008-04-21
CN1675171A (zh) 2005-09-28
AU2003240099B2 (en) 2007-02-01
NO20045353L (no) 2005-01-20
KR20050014013A (ko) 2005-02-05
RU2004137094A (ru) 2005-08-10
DK1517883T3 (da) 2008-05-26
EP1517883B8 (en) 2008-05-21
EP1517883A1 (en) 2005-03-30
ATE386013T1 (de) 2008-03-15
DE60319084D1 (de) 2008-03-27
HK1073838A1 (en) 2005-10-21
CA2489834C (en) 2006-10-03
JP3782818B2 (ja) 2006-06-07
EP1517883B1 (en) 2008-02-13
TW200409747A (en) 2004-06-16
MXPA04012686A (es) 2005-03-23
US20050256198A1 (en) 2005-11-17
JP2006182782A (ja) 2006-07-13
CN1319938C (zh) 2007-06-06
JP2005529970A (ja) 2005-10-06
US7355069B2 (en) 2008-04-08
TWI282784B (en) 2007-06-21
ES2299702T3 (es) 2008-06-01
PL375074A1 (en) 2005-11-14
BR0311932A (pt) 2005-03-22
IL165671A0 (en) 2006-01-15
IS7627A (is) 2005-01-05
DE60319084T2 (de) 2009-01-29
AU2003240099A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
ES2188005T3 (es) Derivados de amidas para el tratamiento de enfermedades mediadas por citoquinas.
UY26727A1 (es) Derivados de tropano útiles en terapia
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
CO5580820A2 (es) Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen
AR051248A1 (es) Derivados de 3-arilamino piridina
AR061374A1 (es) Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos
HUP0300920A1 (hu) Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
UY28369A1 (es) Agentes terapéuticos
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
ES2080900T3 (es) Derivados piranicos utiles como inhibidores de 5-lipoxigenasa.
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
AR044342A1 (es) Derivados de bencimidazol
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR029412A1 (es) Forma cristalina
AR043430A1 (es) Derivados de diarilcicloalquilo, procesos para su preparacion y su uso como agentes farmaceuticos
AR036176A1 (es) Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado
AR039713A1 (es) Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina
AR029005A1 (es) FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
AR039714A1 (es) Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal